A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy

NMR in Biomedicine

Volumn 22, Issue 5, 2009, Pages 561-566

  Mancini, Laura ^a,c   Davies, Lawrence ^b   Friedlos, Frank ^b   Falck Miniotis, Maria ^a   Dzik Jurasz, Andrzej S ^a   Springer, Caroline J ^b   Leach, Martin O ^a   Payne, Geoffrey S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

19F MRS; Carboxypeptidase G2; GDEPT; Molecular imaging; Pharmacokinetics

Indexed keywords

19F MRS; ANTICANCER DRUG; BOVINE ALBUMIN; BREAST CARCINOMA CELLS; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE G2; CLINICAL TRIAL; COLON CANCER CELLS; GDEPT; GENE DELIVERY; IN-CELL; IN-VIVO; KEY PROCESS; L-GLUTAMIC ACIDS; MINIMALLY INVASIVE; MOLECULAR IMAGING; MR SIGNALS; NON-TOXIC PRODUCTS; NOVEL TECHNIQUES; PRODRUG ACTIVATION; PRODRUGS; PROTEIN BINDING; SUICIDE GENE THERAPY; THERAPEUTIC AGENTS;

AMINATION; AMINES; BIOCHEMISTRY; CELLS; CHEMICAL ACTIVATION; CHEMICAL SHIFT; CYTOLOGY; ENZYMES; GENE TRANSFER; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE DETECTORS; PHARMACOKINETICS; SUBSTRATES;

DRUG THERAPY;

4 [BIS(2 CHLOROETHYL)AMINO] 3,5 DIFLUOROBENZOIC ACID; 4 [BIS(2 CHLOROETHYL)AMINO] 3,5 DIFLUOROBENZOYL GLUTAMIC ACID; 4 [BIS(2 HYDROXYETHYL)AMINO] 3,5 DIFLUOROBENZOIC ACID; 4 [BIS(2 HYDROXYETHYL)AMINO] 3,5 DIFLUOROBENZOYL GLUTAMIC ACID; CARBOXYPEPTIDASE G2; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVATION; DRUG HALF LIFE; ENZYME SUBSTRATE; FLUORINE NUCLEAR MAGNETIC RESONANCE; GENE DELIVERY SYSTEM; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; MOLECULAR IMAGING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; SUICIDE GENE THERAPY;

BUFFERS; CELL LINE, TUMOR; FLUORINE; GAMMA-GLUTAMYL HYDROLASE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; PRODRUGS; SOLUTIONS;

BOVINAE;

EID: 68149161166     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1375     Document Type: Article

References (17)

1. Niculescu-Duvaz I, Cooper RG, Stribbling SM, Heyes JA, Metcalfe JA, Springer CJ. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Opin. Mol. Ther. 1999; 1: 480-486.
2. Blaese RM, Culver KW, Ishii H, Oldfield EH, Ram Z, Wallbridge S. Brain tumor treatment: significant contributions. Science 1992; 258: 1960.
3. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, Lemoine NR. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin. Oncol. 1999; 17: 2180-2189.
4. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol. Biotechnol. 2005; 30: 71-88.
5. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349-359.
6. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol. Aspects Med. 2007; 28: 4-41.
7. Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 1996; 56: 4735-4742.
8. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl. Cancer Inst. 2006; 98: 580-598.
9. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann. Oncol. 1993; 4: 597-602.
10. Presant CA, Wolf W, Waluch V, Wiseman C, Kennedy P, Blayney D, Brechner RR. Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 1994; 343: 1184-1187.
11. 19F magnetic resonance spectroscopy. Br. J. Clin. Pharmacol. 2005; 59: 244-248.
12. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, Workman P. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin. Cancer Res. 2003; 9: 5101-5112.
13. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, Tjuvajev JG, Ross BD. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U S A. 1999; 96: 9821-9826.
14. Davies LC, Friedlos F, Hedley D, Martin J, Ogilvie LM, Scanlon IJ, Springer CJ. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. J. Med. Chem. 2005; 48: 5321-5328.
15. Friedlos F, Davies L, Scanlon I, Ogilvie LM, Martin J, Stribbling SM, Spooner RA, Niculescu-Duvaz I, Marais R, Springer CJ. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 2002; 62: 1724-1729.
16. Oconnor CJ, Denny WA, Fan JY, Gravatt GL, Grigor BA, McLennan DJ. Hydrolysis and alkylating reactivity of aromatic nitrogen mustards. J. Chem. Soc. Perkin Trans. 2 1991; 1933-1939.
17. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990; 82: 1107-1112.